Utility of Human Epidermal Growth Factor Receptor 2 (HER2) Retesting of Histologic Grade 3 Invasive Breast Carcinomas.

CONCLUSION: The rate of clinically significant HER2 status discordance between core biopsy and surgical specimens in patients with Grade 3 breast carcinoma is low. However, given the dramatically improved survival conferred by trastuzumab therapy, our findings support reflex HER2 testing of surgical specimens for patients with core biopsy-diagnosed HER2-negative breast carcinoma. PMID: 30624197 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/30624197?dopt=Abstract

Source: The Permanente journal - January 10, 2019 Category: General Medicine Tags: Perm J Source Type: research